Pharmaceuticals (Sep 2022)

Synthesis of Novel <i>N</i><sup>4</sup>-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents

  • Franck Amblard,
  • Julia C. LeCher,
  • Ramyani De,
  • Shu Ling Goh,
  • Chengwei Li,
  • Mahesh Kasthuri,
  • Nicolas Biteau,
  • Longhu Zhou,
  • Zahira Tber,
  • Jessica Downs-Bowen,
  • Keivan Zandi,
  • Raymond F. Schinazi

DOI
https://doi.org/10.3390/ph15091144
Journal volume & issue
Vol. 15, no. 9
p. 1144

Abstract

Read online

Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N4-hydroxycytidine (NHC), was recently emergency-use approved for the treatment of early SARS-CoV-2 infections. Herein, we report the synthesis and evaluation of a series of novel NHC analogs.

Keywords